Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.62 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3789614 | 0.89 | CYP2A6 (0.58) | CYP2A6IDO1ALDH1A1CHRNA7SMN1; SMN2 | |
| SCHEMBL368354 | 0.87 | CYP2A6 (0.56) | CYP2A6IDO1ALDH1A1CHRNA7SMN1; SMN2 | |
| SCHEMBL9347729 | 0.85 | CYP2A6 (0.55) | CYP2A6IDO1ALDH1A1CHRNA7SMN1; SMN2 | |
| SCHEMBL9347766 | 0.85 | CYP2A6 (0.55) | CYP2A6IDO1ALDH1A1CHRNA7SMN1; SMN2 | |
| SCHEMBL8870175 | 0.84 | IDO1 (0.57) | CYP2A6IDO1ALDH1A1CHRNA7SMN1; SMN2 | |
| SCHEMBL91157 | 0.83 | CYP2A6 (0.67) | CYP2A6IDO1ALDH1A1CHRNA7SMN1; SMN2 | |
| SCHEMBL25029575 | 0.81 | CYP2A6 (0.50) | CYP2A6IDO1ALDH1A1CHRNA7SMN1; SMN2 | |
| SCHEMBL25029850 | 0.80 | ALDH1A1 (0.58) | CYP2A6IDO1ALDH1A1CHRNA7SMN1; SMN2 | |
| SCHEMBL1304400 | 0.80 | CYP2A6 (0.62) | CYP2A6IDO1ALDH1A1CHRNA7SMN1; SMN2 | |
| SCHEMBL7845291 | 0.80 | CYP2A6 (0.62) | CYP2A6IDO1ALDH1A1CHRNA7SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021163727-A1 | PIKFYVE KINASE INHIBITORS | AcuraStem Incorporated (US) | 2021-08-19 | — | — | WO | disclosed |
| US-20170114054-A1 | SUBSTITUTED PYRIDINONES AS MGAT2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-04-27 | — | — | US | disclosed |
| US-20150368262-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | Prism BioLab Co., Ltd. (JP) | 2015-12-24 | — | — | US | disclosed |
| US-9040531-B2 | Alpha helix mimetics and methods relating thereto | Prism BioLab Co., Ltd. (JP) | 2015-05-26 | — | — | US | disclosed |
| EP-1919492-B1 | GROWTH HORMONE SECRETAGOGUES | IPSEN PHARMA (FR) | 2013-03-06 | — | — | EP | disclosed |
| US-20130030008-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2013-01-31 | — | — | US | disclosed |
| US-8362073-B2 | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2013-01-29 | — | — | US | disclosed |
| US-20120226066-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MARSAULT ERIC (CA) | 2012-09-06 | — | — | US | disclosed |
| US-20120226072-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MARSAULT ERIC (CA) | 2012-09-06 | — | — | US | disclosed |
| US-20120226067-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MARSAULT ERIC (CA) | 2012-09-06 | — | — | US | disclosed |
| US-20090240027-A1 | INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | TRANZYME PHARMA INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090192138-A1 | COMPOUNDS | BAESCHLIN DANIEL KASPAR | 2009-07-30 | — | — | US | disclosed |
| US-20090137835-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | TRANZYME PHARMA INC. | 2009-05-28 | — | — | US | disclosed |
| US-7521420-B2 | Macrocyclic antagonists of the motilin receptor | TRANZYME PHARMA, INC. (CA) | 2009-04-21 | — | — | US | disclosed |
| WO-2007071738-A1 | CONDENSED HETEROCYCLIC COMPOUNDS USEFUL AS DPP-IV INHIBITORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007061360-A2 | NOVEL 3-BICYCLOCARBONYLAMINOPYRIDINE-2-CARBOXAMIDES OR 3-BICYCLOCARBONYLAMINOPYRAZINE-2-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007014258-A2 | GROWTH HORMONE SECRETAGOGUES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S. (FR) | 2007-02-01 | — | — | WO | disclosed |
| US-20060052509-A1 | Composition containing carbon nanotubes having coating thereof and process for producing them | MITSUBISHI RAYON CO., LTD. (JP) | 2006-03-09 | — | — | US | disclosed |
| CN-1144791-C | Triazole compounds and use thereof as dopamine-D3-ligands | BASF | 2004-04-07 | — | — | CN | disclosed |
| WO-2001007431-A2 | BENZOTHIOPHENE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137835-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | CYP2A6 1454/4885IDO1 3504/4885ALDH1A1 2978/4885 |
| US-20150368262-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | CYP2A6 2913/4885IDO1 2687/4885ALDH1A1 1511/4885 |
| US-20170114054-A1 | SUBSTITUTED PYRIDINONES AS MGAT2 INHIBITORS | PLAAT2, ACAT2, MGAT2 | CYP2A6 302/4885IDO1 801/4885ALDH1A1 534/4885 |
| US-20120226066-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | CYP2A6 1454/4885IDO1 3504/4885ALDH1A1 2978/4885 |
| US-20090192138-A1 | COMPOUNDS | DPP4, DPP3, DPP8 | CYP2A6 836/4885IDO1 702/4885ALDH1A1 363/4885 |
| US-20090240027-A1 | INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CCKAR, CHRM2 | CYP2A6 1985/4885IDO1 3207/4885ALDH1A1 2729/4885 |
| US-20120226067-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CCKAR | CYP2A6 1527/4885IDO1 3184/4885ALDH1A1 3005/4885 |
| US-20130030008-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | EDF1, LPAR2, LIPG | CYP2A6 2339/4885IDO1 1180/4885ALDH1A1 2149/4885 |
| US-20120226072-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | CYP2A6 1454/4885IDO1 3504/4885ALDH1A1 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.